Japer Therapeutics, Inc. Warrants (JSPRW)
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Pomerantz Law Firm is investigating potential securities fraud at Jasper Therapeutics after the company reported data issues in a drug study, causing its stock to drop 55.1%.
Jasper Reports Wider Loss in Fiscal Q2
Jasper Therapeutics reported a net loss of $1.74 per share in Q2 2025, with no revenue generated. The company is focusing exclusively on briquilimab, a monoclonal antibody for mast cell-driven diseases, while implementing significant cost-cutting measures.